Hyperfine (NASDAQ:HYPR) Releases Earnings Results, Hits Estimates

by · The Markets Daily

Hyperfine (NASDAQ:HYPR – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09), FiscalAI reports. The company had revenue of $3.90 million for the quarter, compared to analyst estimates of $4.13 million. Hyperfine had a negative net margin of 226.88% and a negative return on equity of 98.83%.

Here are the key takeaways from Hyperfine’s conference call:

  • Revenue rose 45% year over year to $3.9 million in Q2, while system sales increased 50% to 12 units; first-half revenue reached $7.8 million.
  • Gross margin remained above 50% for the fourth consecutive quarter at 50.7%, while first-half cash burn improved approximately 9% year over year to $16.6 million.
  • Management reiterated 2026 revenue guidance of $20 million to $22 million, gross margin of 50% to 55%, cash burn of $26 million to $28 million, and cash runway extending into 2028.
  • Growth is broadening across hospitals and IDNs, neurology offices, and international markets; the company cited initial large-IDN adoption, more than a dozen office placements, and first European Model 2 sales.
  • Hyperfine remains loss-making, reporting a $9.3 million quarterly net loss, and its stronger cash position partly reflects $10.6 million raised through its ATM program, which may create shareholder dilution.

Hyperfine Stock Up 0.2%

Shares of HYPR stock traded up $0.00 during trading hours on Thursday, reaching $0.98. 373,535 shares of the company’s stock were exchanged, compared to its average volume of 769,529. The stock’s 50 day moving average is $1.24 and its 200-day moving average is $1.25. The company has a market cap of $97.48 million, a price-to-earnings ratio of -2.40 and a beta of 1.42. The company has a current ratio of 5.52, a quick ratio of 4.90 and a debt-to-equity ratio of 0.38. Hyperfine has a fifty-two week low of $0.85 and a fifty-two week high of $2.22.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. EP Wealth Advisors LLC acquired a new position in Hyperfine during the 4th quarter valued at about $34,000. Millennium Management LLC purchased a new stake in Hyperfine in the fourth quarter valued at about $55,000. Cerity Partners LLC acquired a new stake in Hyperfine in the fourth quarter worth about $59,000. XTX Topco Ltd boosted its holdings in Hyperfine by 47.9% in the fourth quarter. XTX Topco Ltd now owns 80,735 shares of the company’s stock worth $79,000 after acquiring an additional 26,165 shares in the last quarter. Finally, Bridgeway Capital Management LLC grew its stake in shares of Hyperfine by 50.2% during the fourth quarter. Bridgeway Capital Management LLC now owns 119,700 shares of the company’s stock worth $117,000 after acquiring an additional 40,000 shares during the last quarter. 15.03% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Hyperfine in a report on Friday, July 17th. B. Riley Financial reissued a “buy” rating on shares of Hyperfine in a research report on Wednesday, May 13th. Finally, BTIG Research assumed coverage on Hyperfine in a research note on Wednesday, April 29th. They set a “buy” rating and a $2.00 price objective for the company. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $1.78.

Check Out Our Latest Report on Hyperfine

Hyperfine Company Profile

(Get Free Report)

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.

The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.

Featured Articles